Core Viewpoint - Kingsray Biotechnology (01548) announced that its affiliate Legend Biotech Corporation will present long-term follow-up clinical and translational research data from the CARTITUDE-1 and CARTITUDE-4 studies on CARVYKTI (cilta-cel) for patients with relapsed or refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) annual meeting on December 6, 2025 [1] Group 1 - Legend Biotech will showcase the latest results from the Phase III study CARTITUDE-4, along with six posters demonstrating the durability of response data for CARVYKTI across different subgroups and real-world study results [1] - The presentation will also include initial human trial data for the dual-target allogeneic CAR-T candidate product LUCAR-G39D [1]

Core Viewpoint - Legend Biotech announced the presentation of long-term follow-up clinical and translational research data for CARVYKTI (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) annual meeting on December 6, 2025 [1] Group 1: Clinical Research Findings - The CARTITUDE-1 and CARTITUDE-4 studies provided significant data on the efficacy of CARVYKTI in RRMM patients [1] - The latest results from the Phase III study CARTITUDE-4 were also presented, highlighting the ongoing research into the treatment's effectiveness [1] - Six posters were showcased, demonstrating the durability of response data for CARVYKTI across different subgroups and real-world studies [1] Group 2: New Product Development - Legend Biotech presented initial human trial data for the dual-target allogeneic CAR-T candidate product LUCAR-G39D at the ASH annual meeting [1]

Group 1 - The Hong Kong stock market for innovative drugs has seen significant gains, with notable increases in shares of companies such as CSPC Pharmaceutical Group rising over 13%, Lepu Biopharma increasing by 9%, and King’s Ray Biotechnology up over 5% [1] - Various Hong Kong innovative drug ETFs have also performed well, with several funds, including GF Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, rising over 2% [1][2] - The approval of CSPC's adenosylcobalamin capsules by the National Medical Products Administration of China is expected to enhance the company's product line in the blood and nervous system treatment areas [4] Group 2 - Lepu Biopharma announced that its candidate drug MRG003, an innovative antibody-drug conjugate for treating recurrent or metastatic nasopharyngeal carcinoma, will present key clinical research results at the 2025 American Society of Clinical Oncology annual meeting [4] - King’s Ray Biotechnology reported that its affiliate Legend Biotech submitted a 6-K form to the SEC, revealing long-term results from the CARTITUDE-1 study, indicating that one-third of patients did not experience disease progression for five years or more after a single CARVYKTI infusion [5] - According to research reports, the pharmaceutical sector is expected to experience a turning point this year, with strong growth in profitability anticipated over the next two years, driven by favorable policies and macroeconomic recovery [5][6]